Largest Indian CRDMO platform offering comprehensive solutions across the drug development lifecycle for both small molecules and biologics with a "follow the customer" model.
Leading CRO platform in India powered by advanced capabilities and superior scientific talent.
Scalable CDMO solutions comprising small molecules and differentiated gene-to-GMP biologics capabilities with a distinctive US-India delivery model.
Diversified revenue profile with deep and long-standing relationships with global pharmaceutical customers and proven `Follow the customer' model
Strategically located advanced infrastructure across India and United states with strong track record of regulatory compliance.
Professional management for long term sustainable performance.
The company is dependent on the continued outsourcing of research and development by innovator pharmaceutical and biotechnology companies. The company derived a substantial portion of its revenue from operations from the company CRO solutions in Fiscals 2026, 2025 and 2024 representing 64.51%, 65.78% and 67.15%, respectively, of its revenue from operations. Any adverse trends in the outsourcing practices or reduction in demand for outsourcing by innovator pharmaceutical and biotechnology companies could adversely affect the company's business, results of operations, cash flows and financial condition.
The company derives a significant portion of its revenue from operations from customers outside India, particularly from North America and Europe. While revenue from operations from North America represented 54.80%, 60.08% and 55.19% of the company's revenue from operations in Fiscals 2026, 2025 and 2024, respectively, revenue from operations from Europe represented 29.67%, 22.24% and 27.19% of its revenue from operations in Fiscals 2026, 2025 and 2024, respectively. Any adverse developments in these international markets could impact the demand for the company's solutions which in turn could have an adverse effect on its business, financial condition, cash flows and results of operations.
The company depends on certain key customers for a significant portion of its revenue from operations (the company's top ten customers contributed to 43.29%, 35.41% and 31.36% of its revenue from operations in Fiscals 2026, 2025 and 2024, respectively). Any decrease in revenue from any of the company's key customers or any loss of these customers may adversely affect its business, results of operations, cash flows and financial condition.
The company is subject to strict technical specifications and quality requirements, and its manufacturing facilities and equipment are subject to periodic inspections and audits by regulatory authorities and the company's customers. Any manufacturing or quality control failures may subject it to regulatory action or termination of customer contracts any of which could have an adverse effect on the company's reputation, business, results of operations, cash flows and financial condition.
The company is highly dependent on its skilled personnel, in particular the company's scientific personnel, for its day-to-day operations. The loss of, or the company's inability to attract or retain such persons may have a material adverse effect on its business, results of operations, cash flows and financial condition.
Any inability of the company's customers to develop or manufacture commercially viable drugs may adversely affect outsourcing needs and its development and manufacturing revenue and consequently, the company's business, financial condition, results of operations and cash flows.
The company R&D and manufacturing facilities are essential to its business. Any disruption or interruption in the continuous operations of the company R&D and manufacturing facilities would have a material adverse effect on its business, results of operations, cash flows and financial condition.
The company compete in a highly competitive market and any failures to successfully compete with other industry players or to maintain pricing discipline in the faces of competitive pressures could materially adversely affect its margins, business, results of operations, cash flows and financial condition.
The company failures to protect its customers trade secrets, sensitive information and other confidential information, or any infringement or misappropriation claims, could erode the company competitive advantage and adversely affect its reputation, business, results of operations, cash flows and financial condition.
The company relies on domestic and international third-party suppliers for its raw materials that contribute to a significant portion of the company's total purchases (its top ten suppliers contributed to 32.91%, 33.73% and 27.56% of the company's total purchases in Fiscals 2026, 2025 and 2024, respectively). Any inability to retain key suppliers or identify alternate sourcing arrangements for critical raw materials could adversely affect the company's business, results of operations, cash flows and financial condition.
